TY - JOUR
T1 - Wearing blue light-blocking glasses in the evening advances circadian rhythms in the patients with delayed sleep phase disorder
T2 - An open-label trial
AU - Esaki, Yuichi
AU - Kitajima, Tsuyoshi
AU - Ito, Yasuhiro
AU - Koike, Shigefumi
AU - Nakao, Yasumi
AU - Tsuchiya, Akiko
AU - Hirose, Marina
AU - Iwata, Nakao
N1 - Publisher Copyright:
© 2016 Taylor & Francis Group, LLC.
PY - 2016/9/13
Y1 - 2016/9/13
N2 - It has been recently discovered that blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We investigated the effect of blue light-blocking glasses in subjects with delayed sleep phase disorder (DSPD). This open-label trial was conducted over 4 consecutive weeks. The DSPD patients were instructed to wear blue light-blocking amber glasses from 21:00 p.m. to bedtime, every evening for 2 weeks. To ascertain the outcome of this intervention, we measured dim light melatonin onset (DLMO) and actigraphic sleep data at baseline and after the treatment. Nine consecutive DSPD patients participated in this study. Most subjects could complete the treatment with the exception of one patient who hoped for changing to drug therapy before the treatment was completed. The patients who used amber lens showed an advance of 78 min in DLMO value, although the change was not statistically significant (p = 0.145). Nevertheless, the sleep onset time measured by actigraph was advanced by 132 min after the treatment (p = 0.034). These data suggest that wearing amber lenses may be an effective and safe intervention for the patients with DSPD. These findings also warrant replication in a larger patient cohort with controlled observations.
AB - It has been recently discovered that blue wavelengths form the portion of the visible electromagnetic spectrum that most potently regulates circadian rhythm. We investigated the effect of blue light-blocking glasses in subjects with delayed sleep phase disorder (DSPD). This open-label trial was conducted over 4 consecutive weeks. The DSPD patients were instructed to wear blue light-blocking amber glasses from 21:00 p.m. to bedtime, every evening for 2 weeks. To ascertain the outcome of this intervention, we measured dim light melatonin onset (DLMO) and actigraphic sleep data at baseline and after the treatment. Nine consecutive DSPD patients participated in this study. Most subjects could complete the treatment with the exception of one patient who hoped for changing to drug therapy before the treatment was completed. The patients who used amber lens showed an advance of 78 min in DLMO value, although the change was not statistically significant (p = 0.145). Nevertheless, the sleep onset time measured by actigraph was advanced by 132 min after the treatment (p = 0.034). These data suggest that wearing amber lenses may be an effective and safe intervention for the patients with DSPD. These findings also warrant replication in a larger patient cohort with controlled observations.
UR - http://www.scopus.com/inward/record.url?scp=84975230414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975230414&partnerID=8YFLogxK
U2 - 10.1080/07420528.2016.1194289
DO - 10.1080/07420528.2016.1194289
M3 - Article
C2 - 27322730
AN - SCOPUS:84975230414
SN - 0742-0528
VL - 33
SP - 1037
EP - 1044
JO - Chronobiology International
JF - Chronobiology International
IS - 8
ER -